Masimo Corporation (MASI - Analyst Report), a leader in non-invasive monitoring technology for patient care, together with University Children's Hospital Basel in Basel, Switzerland, recently reported that the hospital was the first pediatric institution in the region to utilize in its general wards Masimo Patient SafetyNet.
Masimo Patient SafetyNet combines Masimo SET pulse oximetry with wireless notification and monitoring of ventilation.
The operationalization at the University Children's Hospital Basel, locally the Universitats-Kinderspital Beider Basel (UKBB), occurred after an exhaustive study which led to the adoption of Masimo SET pulse oximetry at the facility. The Children’s Hospital Basel partners the University of Basel.
Masimo is a market leader in the pulse oximetry monitoring equipment industry. The company’s prospects are encouraging, given the sizeable global market opportunity, adoption of pulse oximetry in non-critical areas of the hospital and growing barriers to entry due to additional non-invasive parameters.
While Masimo’s patented SET offering remains its mainstay, the rainbow measurements represent another growth driver. However, the company’s reliance on third-party providers like OEMs for a part of its business raises concern and the royalty stream is no longer as attractive as before.
In May 2013, Covidien plc (COV - Analyst Report) won the approval of the U.S. Food and Drug Administration (FDA) for its motion-tolerant Nellcor pulse oximetry devices. The system can effectively detect and diagnose acute and potentially fatal breathing difficulties at an early stage, thereby allowing faster treatment and elimination of respiratory complications.
The Nellcor Bedside SpO2 Patient Monitoring System, Bedside Respiratory Patient Monitoring System and N-600x Pulse Oximetry Monitoring System are the devices that have been cleared by the FDA. The systems continuously monitor pulse rate and other parameters for adult, neonatal and pediatric patients.
The stock carries a Zacks Rank #4 (Sell). We are more positive about Heartware International Inc. (HTWR - Snapshot Report) and Intuitive Surgical, Inc. (ISRG - Analyst Report) each of which carry a Zacks Rank #2 (Buy) and are expected to do well.